VKTX Initiates Phase 1 Study
Viking Therapeutics initiates Phase 1 study to evaluate novel amylin receptor agonist VK3019 in healthy adults
VKTX VKTX - Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults